P L McCarthy
Overview
Explore the profile of P L McCarthy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1005
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Musto P, Anderson K, Attal M, Richardson P, Badros A, Hou J, et al.
Ann Oncol
. 2017 May;
29(4):1074.
PMID: 28541409
No abstract available.
2.
Musto P, Anderson K, Attal M, Richardson P, Badros A, Hou J, et al.
Ann Oncol
. 2016 Nov;
28(2):228-245.
PMID: 27864218
Background: Therapeutic advancements following the introduction of autologous stem cell transplantation and 'novel' agents have significantly improved clinical outcomes for patients with multiple myeloma (MM). Increased life expectancy, however, has...
3.
Denzen E, Thao V, Hahn T, Lee S, McCarthy P, Rizzo J, et al.
Bone Marrow Transplant
. 2016 Apr;
51(9):1233-40.
PMID: 27088381
Hematopoietic cell transplantation (HCT) is a procedure that can significantly influence the socioeconomic wellbeing of patients, caregivers and their families. Among 30 allogeneic HCT recipients and their caregivers enrolled on...
4.
Mohty M, Richardson P, McCarthy P, Attal M
Bone Marrow Transplant
. 2015 Apr;
50(8):1024-9.
PMID: 25893452
Novel agents including proteasome inhibitors and immunomodulatory drugs are now routinely utilized as part of the induction regimen before transplantation and this has resulted in substantial improvements in the depth...
5.
Hong S, Le-Rademacher J, Artz A, McCarthy P, Logan B, Pasquini M
Bone Marrow Transplant
. 2014 Dec;
50(3):367-74.
PMID: 25437248
Hematopoietic cell transplantation (HCT) with non-myeloablative (NMA) conditioning for lymphoproliferative diseases (LD) includes fludarabine with and without low-dose TBI. Transplant outcomes were compared among patients aged ⩾40 years with LD...
6.
Fleischhauer K, Fernandez-Vina M, Wang T, Haagenson M, Battiwalla M, Baxter-Lowe L, et al.
Bone Marrow Transplant
. 2014 Jun;
49(9):1176-83.
PMID: 24955785
HLA-DP antigens are beta-alpha heterodimers encoded by polymorphic HLA-DPB1 and -DPA1 alleles, respectively, in strong linkage disequilibrium (LD) with each other. Non-permissive unrelated donor (UD)-recipient HLA-DPB1 mismatches across three different...
7.
Freytes C, Vesole D, LeRademacher J, Zhong X, Gale R, Kyle R, et al.
Bone Marrow Transplant
. 2013 Nov;
49(3):416-21.
PMID: 24270389
There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or...
8.
Chen G, Zhang Y, Hahn T, Abrams S, ROSS M, Liu H, et al.
Bone Marrow Transplant
. 2013 Oct;
49(2):248-53.
PMID: 24162612
MTX is a standard component of acute GVHD prophylaxis. However, its use can be limited by toxicity. On the basis of disease risk, we prospectively assigned 132 consecutive patients from...
9.
Loren A, Brazauskas R, Chow E, Gilleece M, Halter J, Jacobsohn D, et al.
Bone Marrow Transplant
. 2013 Feb;
48(8):1091-7.
PMID: 23419436
Physician practice variation may be a barrier to informing hematopoietic cell transplant (HCT) recipients about fertility preservation (FP) options. We surveyed HCT physicians in the United States to evaluate FP...
10.
Akpek G, Pasquini M, Logan B, Agovi M, Lazarus H, Marks D, et al.
Bone Marrow Transplant
. 2012 Dec;
48(6):825-31.
PMID: 23222382
To assess the impact of spleen status on engraftment, and early morbidity and mortality after allogeneic hematopoietic cell transplantation (HCT), we analyzed 9,683 myeloablative allograft recipients from 1990 to 2006;...